Get the Stockscreener App
0.794
0.66%
0.0052
Elutia Inc stock is traded at $0.794, with a volume of 86,602.
It is up +0.66% in the last 24 hours and down -1.98% over the past month.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
See More
Previous Close:
$0.7888
Open:
$0.799
24h Volume:
86,602
Relative Volume:
0.56
Market Cap:
$35.17M
Revenue:
$15.97M
Net Income/Loss:
$-24.40M
P/E Ratio:
-1.0468
EPS:
-0.7585
Net Cash Flow:
$-45.82M
1W Performance:
-3.54%
1M Performance:
-1.98%
6M Performance:
-32.14%
1Y Performance:
-11.79%
1-Day Range:
$0.7426
$0.8099
1-Week Range:
$0.7105
$0.8099
52-Week Range:
$0.50
$1.385
Elutia Inc Stock (ELUT) Company Profile
Name
Elutia Inc
Sector
Industry
Phone
240-247-1143
Address
12510 PROSPERITY DRIVE, SILVER SPRING
Compare ELUT vs ABT, MDT, SYK, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELUT
Elutia Inc
|
0.794 | 35.17M | 15.97M | -24.40M | -45.82M | -0.7585 |
ABT
Abbott Laboratories
|
104.89 | 181.50B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.75 | 121.20B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
294.66 | 113.02B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.39 | 64.33B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.60 | 49.92B | 6.30B | 1.07B | 1.09B | 1.8406 |
Elutia Inc Stock (ELUT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-02-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-02-20 | Initiated | Cowen | Outperform |
| Nov-02-20 | Initiated | Piper Sandler | Overweight |
| Nov-02-20 | Initiated | Truist | Buy |
Elutia Inc Stock (ELUT) Latest News
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - The Manila Times
The buyer releases $8 million held back from Elutia's sale. Elutia believes funding extends into 2029. - stocktitan.net
Elutia Receives $8 Million Payment from Boston Scientific; Company Now Fully Funded into 2029 - GlobeNewswire
Press Release: Elutia Receives $8 Million Payment From Boston Scientific; Company Now Fully Funded Into 2029 - Moomoo
ELUT 8-K及美國證券交易委員會申報文件 - Yahoo 財經
ELUT: Drug-eluting biomatrix targets surgical infections, with strong demand and full funding to launch - TradingView
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com India
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com Canada
Elutia at H.C. Wainwright conference: capital, data and launch path By Investing.com - Investing.com UK
Elutia to Present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15th - marketscreener.com
Elutia will discuss how to address infections after reconstructive surgery - Stock Titan
Post-surgical infections will be discussed at Elutia's upcoming talks - Stock Titan
Elutia (ELUT) Holds Steady at $0.88 as Shares Consolidate Between Support and ResistanceCall Wall - dars.gov.et
Elutia Inc. Earnings Call Highlights Funding, NXT Outlook - TipRanks
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotSwing Entry Signals - vinanet.vn
Elutia (ELUT) Move: Moves 2.32% Lower to $0.90; Price Levels: Traders Can Monitor the $0.85-$0.95 Range under the Current SnapshotStock Picks - siam.in
Elutia (ELUT) Q2 2026 Earnings Call Transcript - The Globe and Mail
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - Sahm
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Gain Therapeutics (GANX), Summit Therapeutics (SMMT) and Elutia (ELUT) - The Globe and Mail
Cellution Biologics Acquires SimpliDerm From Elutia for Up to $11 Million - citybiz
ELUT Looks 5.6% Overvalued on GF Value™ - GuruFocus
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - The Manila Times
Cellution Biologics Completes Acquisition of SimpliDerm® from Elutia Inc. - mykxlg.com
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia Flat on Sale to Cellution - Baystreet.ca
Elutia sells SimpliDerm business for up to $11 million - Investing.com
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com India
Elutia sells SimpliDerm business for up to $11 million By Investing.com - Investing.com Canada
Elutia gets $8 million at closing as FDA clearance is expected in 2027 - Stock Titan
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 Million in Cash to Fund NXT-41x Through Full Commercial Launch - The Manila Times
Elutia Completes SimpliDerm® Sale on Schedule, Adds $8 - GlobeNewswire
SILVERARC CAPITAL MANAGEMENT, LLC Trims Elutia Inc (ELUT) Stake -- Shares Look 11% Overvalued on GF Value - GuruFocus
Cellution Biologics Llc completed the acquisition of SimpliDerm human acellular dermal matrix business of Elutia Inc. for $11 million. - marketscreener.com
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Earnings Outlook Update - vinanet.vn
Elutia (ELUT) Q2 2026 Earnings: Wider-Than-Expected Loss as Shares Advance 1.49%Estimate Dispersion - dars.gov.et
Elutia Inc (ELUT) Stock News Today - TradingKey
Elutia Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ELUT) 2026-08-16 - Seeking Alpha
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Downgrade: What You Need To Know About The Latest Elutia Inc. (NASDAQ:ELUT) Forecasts - simplywall.st
Elutia secures $26M to launch NXT-41x, targetin... - Pluang
Elutia Secures Up to $26 Million to Fund NXT-41x Through Commercial Launch; Reports Second Quarter 2026 Results - Sahm
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com Australia
Elutia Inc. (ELUT): SilverArc Capital reports 4.9% stake in Class A shares - Stock Titan
Elutia Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic - GuruFocus
Elutia Inc (ELUT) (Q2 2026) Earnings Call Highlights: Strategic Pivot to NXT41X Drives Strong ... By GuruFocus - Investing.com Canada
ELUT Looks 2.2% Undervalued on GF Value™ Amid Challenging Sales and Cash Flow - GuruFocus
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com India
Elutia Q2 2026 slides: $26M capital raise funds NXT41x launch - Investing.com South Africa
Elutia Inc. (NASDAQ: ELUT) Share Price, ELUT Stock News, ELUT Share Price & Updates - kalkine.ca
Elutia Inc Stock (ELUT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Elutia Inc Stock (ELUT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| NEELS GUIDO J | Director |
Jan 30 '26 |
Buy |
1.04 |
20,000 |
20,800 |
118,750 |
| NEELS GUIDO J | Director |
Jan 29 '26 |
Buy |
1.06 |
15,000 |
15,900 |
98,750 |
| NEELS GUIDO J | Director |
Jan 28 '26 |
Buy |
1.06 |
15,000 |
15,900 |
83,750 |
| William Matthew Zuga | Former Director |
Dec 23 '25 |
Proposed Sale |
0.55 |
12,613 |
6,937 |
0 |
| RAKIN KEVIN | Director |
Dec 17 '25 |
Buy |
0.52 |
50,000 |
25,995 |
322,419 |
| Colpman David | Director |
Dec 17 '25 |
Buy |
0.51 |
12,500 |
6,375 |
31,098 |
| Makes Brigid | Director |
Dec 17 '25 |
Buy |
0.52 |
25,000 |
13,000 |
27,000 |
| Mills C Randal | PRESIDENT AND CEO |
Dec 17 '25 |
Buy |
0.51 |
3,000 |
1,530 |
379,204 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Dec 17 '25 |
Buy |
0.53 |
60,000 |
31,800 |
447,110 |
| Ferguson Matthew | CHIEF FINANCIAL OFFICER |
Dec 02 '25 |
Buy |
0.67 |
5,500 |
3,685 |
379,071 |
0.84%
7.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):